Belite Bio, Inc
BLTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $30 | $25 | $9 | $7 |
| G&A Expenses | $10 | $7 | $4 | $2 |
| SG&A Expenses | $10 | $7 | $4 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $40 | $32 | $13 | $10 |
| Operating Income | -$40 | -$32 | -$13 | -$10 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $0 | $0 | $0 |
| Pre-Tax Income | -$36 | -$32 | -$13 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | -$32 | -$13 | -$10 |
| % Margin | – | – | – | – |
| EPS | -1.18 | -1.19 | -0.63 | -0.4 |
| % Growth | 0.8% | -88.9% | -57.5% | – |
| EPS Diluted | -1.18 | -1.19 | -0.63 | -0.4 |
| Weighted Avg Shares Out | 31 | 27 | 20 | 24 |
| Weighted Avg Shares Out Dil | 31 | 27 | 20 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$36 | -$31 | -$12 | -$10 |
| % Margin | – | – | – | – |